Shorter Blood-Thinner Treatment After Stent Placement in Atrial Fibrillation and Heart Attack
Compares one blood thinner against two in people with atrial fibrillation after a heart attack.
Plain-language title generated from the registry record
Registry title: Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI
Key facts
- Where
- Gwangju, South KoreaSee the site
Where in South Korea
- Chonnam National University HospitalGwangju, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chonnam National University Hospital
- Trial code
- NCT07583784
- Record updated
- 2 September 2026
- Original description
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).Read full original descriptionShow less
Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).
Inclusion: Patients aged 19 years old; Patients with AF and CHA2DS2-VA score ≥2; ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI); STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12; NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12; Symptoms of ischemia; New or presumed new significant ST-T wave changes; Development of pathological Q waves on electrocardiography; Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality; Intracoronary thrombus detected on angiography; Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.
Exclusion: Prior history of intracranial hemorrhage; Planned cardiac surgery within 1 year after randomization; Coexisting conditions related to high risk of life-threatening bleeding; Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment); Advanced chronic kidney disease (creatinine clearance <15 ml/min/1.73 m2) or on dialysis; Patients contraindicated for use of DOACs or clopidogrel; Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist; Patients with severe thrombocytopenia or coagulopathy; Liver cirrhosis or severe hepatic dysfunction; Pregnancy or breast feeding; Unwillingness or inability to comply with the procedures described in this protocol.